May 18, 2023

The Honorable Kevin McCarthy
Speaker
U.S. House of Representatives
2468 Rayburn House Office Building
Washington, D.C. 20515

The Honorable Hakeem Jeffries
Minority Leader
U.S. House of Representatives
2433 Rayburn House Office Building
Washington, D.C. 20515

The Honorable Cathy McMorris Rodgers
Chair, Energy & Commerce Committee
U.S. House of Representatives
2125 Rayburn House Office Building
Washington, D.C. 20515

The Honorable Frank Pallone
Ranking Member, Energy & Commerce Committee
U.S. House of Representatives
2107 Rayburn House Office Building
Washington, D.C. 20515

The Honorable Jim Jordan
Chair, Judiciary Committee
U.S. House of Representatives
2138 Rayburn House Office Building
Washington, D.C. 20515

The Honorable Chuck Schumer
Majority Leader
U.S. Senate
322 Hart Senate Office Building
Washington, D.C. 20510

The Honorable Mitch McConnell
Minority Leader
U.S. Senate
317 Russell Senate Office Building
Washington, D.C. 20510

The Honorable Dick Durbin
Chair, Judiciary Committee
U.S. Senate
711 Hart Senate Office Building
Washington, D.C. 20510

The Honorable Lindsey Graham
Ranking Member, Judiciary Committee
U.S. Senate
211 Russell Senate Office Building
Washington, D.C. 20510

The Honorable Jerrold Nadler
Ranking Member, Judiciary Committee
U.S. House of Representatives
2132 Rayburn House Office Building
Washington, D.C. 20515

RE: Support Passage of S. 993/ H.R. 1839- the Combating Illicit Xylazine Act

Dear Speaker, Majority Leader, Minority Leaders, Chairs, and Ranking Members:

We, the undersigned Attorneys General, write you to request that you pass S. 993/ H.R. 1839, the Combating Illicit Xylazine Act, without delay. This bipartisan legislation seeks to curb the proliferation of illicit xylazine by classifying its use as a controlled substance to stop the death that this drug is causing across the United States.

Xylazine is a drug that the Administrator for the Drug Enforcement Administration (the "DEA") recently warned was "making the deadliest drug threat our country has ever
faced, fentanyl, even deadlier." Known on the street as "tranq" or "zombie drug," the DEA believes that xylazine is so dangerous that it recently issued a "Public Safety Alert." For context, the only other "Public Safety Alerts" issued by the DEA in the last three years concerned fentanyl and its rise in use and death. The DEA did so because last year, "approximately 23% of fentanyl powder and 7% of fentanyl pills seized by the DEA contained xylazine." As stated in the alert, xylazine alone or mixed with other drugs, like fentanyl, is dangerous because it is a sedative known to depress breathing, blood pressure, heart rate, and body temperature, as well as cause unconsciousness, necrosis, and death.

Indeed, according to the Centers for Disease Control and Prevention ("CDC"), "because xylazine is not an opioid, it does not respond to opioid reversal agents such as naloxone; therefore, if illicit opioid products containing xylazine are used, naloxone might be less effective in fully reversing an overdose." That report, which looked at 2019 data from the State Unintentional Drug Overdose Reporting System in 38 states and the District of Columbia, found Xylazine in 2% of overdose deaths. However, according to the National Institute on Drug Abuse ("NIDA"), the number of fatalities involving xylazine is increasing exponentially. One study cited by NIDA found xylazine increasingly present, finding it in 25.8% of the overdose deaths in the City of Philadelphia, 19.3% of the overdose deaths in the State of Maryland, and 10.2% of overdose deaths in the State of Connecticut. According to another report by the American Psychiatric Association, xylazine’s prevalence in overdose deaths rose from .36% in 2015 to 6.7% in 2020, almost a nineteen-fold increase.

Xylazine is a non-opioid veterinary tranquilizer for large animals, like horses and deer. It is not approved for human use, and there is no accepted medical use in humans, nor is it currently a controlled substance under the federal Controlled Substances Act (CSA), 21 U.S.C. §813. Some states, such as Florida, have scheduled xylazine as a Schedule 1 controlled substance. Research has shown xylazine is often added to illicit opioids, including most frequently fentanyl, and users report using xylazine-containing Fentanyl to lengthen its euphoric effects. The White House, pursuant to the SUPPORT Act of 2018, recently declared fentanyl-adulterated or fentanyl-associated xylazine (FAAX) an "emerging threat."

---

3 DEA Public Safety Alert, supra note 1.
4 Mbabazi Kariisa et al., Xylazine Detection and Involvement in Drug Overdose Deaths – United States, 2019,
5 Id.
10 Fla. Stat. § 893.03.
Though, as noted by the DEA, there is limited scientific research on the effects of xylazine on the human body, there are anecdotal reports that xylazine users experience effects like opioids.\(^{13}\) There is also some evidence that some people seek out xylazine on its own or combined with heroin because of its effects.\(^{14}\) The DEA has also noted that xylazine users may develop "a physical dependence to xylazine itself, with some users reporting the withdrawal symptoms from xylazine as, or more, severe than from heroin or methadone; symptoms include sharp chest pains and seizures."\(^{15}\) The full extent and nature of psychological or physical dependence that xylazine causes appear to be unknown because of a lack of research and how commonly it is used with other controlled substances.

The Food & Drug Administration (the "FDA") approved xylazine for veterinary use, and thus it is currently readily available for purchase over the Internet sites, often with no association to the veterinary profession nor requirements to prove legitimate need. In a recent intelligence report, the DEA noted, "[a] kilogram of xylazine powder can be purchased online from Chinese suppliers with common prices ranging from $6-$20 U.S. dollars per kilogram."\(^{16}\) Given the low price, the DEA has warned that xylazine's use as an adulterant for other illicit drugs is growing to allow traffickers to increase their profits.\(^{17}\) The increase in deaths caused the FDA to attempt to restrict the unlawful importation of xylazine and restrict importation and distribution to legitimate veterinary use in the United States.\(^{18}\) But, federal authorities are still encountering a rise in xylazine in connection with fentanyl being trafficked from Mexico by the Sinaloa and Jalisco Cartels using chemicals sourced from China.\(^{19}\)

There is limited information regarding the prevalence of xylazine as many States have not tested for its presence in seizures or overdose deaths until recently. The DEA reports that its prevalence is increasing, and 48 out of 50 States have encountered xylazine.\(^{20}\) However, the national statistics on the presence of xylazine in overdose deaths are "widely underestimated" because of limited testing and the variance in testing procedures.\(^{21}\) Despite the limited data, the DEA reported significant increases in xylazine-positive deaths.\(^{22}\)

<table>
<thead>
<tr>
<th>Region</th>
<th>2020</th>
<th>2021</th>
<th>Percent Increase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Northeast</td>
<td>631</td>
<td>1281</td>
<td>103%</td>
</tr>
<tr>
<td>South</td>
<td>116</td>
<td>1423</td>
<td>1127%</td>
</tr>
<tr>
<td>Midwest</td>
<td>57</td>
<td>351</td>
<td>516%</td>
</tr>
<tr>
<td>West</td>
<td>4</td>
<td>34</td>
<td>750%</td>
</tr>
</tbody>
</table>

Many of our States have scheduled xylazine, though some minor disagreement exists over which Schedule to place xylazine. Nevertheless, we agree that Congress must act quickly to classify the illicit use of xylazine under Schedule III of the CSA. The Combating Illicit Xylazine Act provides critical tools that will enable the DEA to track its manufacturing, prevent diversion, and mandate analysis and reporting on the illicit use of xylazine.

The undersigned Attorneys General have a longstanding commitment to helping our communities recover from the opioid epidemic. For years, we have stood on the front line in the fight to end the opioid epidemic. We

---


\(^{14}\) Id. at 1.

\(^{15}\) Id. at 2.

\(^{16}\) Id. at 1.

\(^{17}\) Id.

\(^{18}\) FDA Press Release, supra note 9.

\(^{19}\) DEA Public Safety Alert, supra note 1.

\(^{20}\) Id.

\(^{21}\) Id.

\(^{22}\) Id.
continue to seek accountability from opioid manufacturers, distributors, dispensers, and others in the opioid supply chain for their role in unleashing this epidemic. In addition to the critical injunctive relief imposed upon these companies, billions of dollars are beginning to flow to communities across the country to abate the epidemic.

Xylazine is a growing danger to communities across our nation. With a record number of overdose deaths, we must confront this new threat. Therefore, as Attorneys General of our respective States, we urge you to pass the Combating Illicit Xylazine Act without delay.

The four co-sponsors of this letter – Connecticut, Florida, New York, and Tennessee – are joined by the undersigned attorneys general across the U.S. states and its territories.

Sincerely,

William Tong
Connecticut Attorney General

Ashley Moody
Florida Attorney General

Letitia James
New York Attorney General

Jonathan Skrmetti
Tennessee Attorney General

Steve Marshall
Alabama Attorney General

Treg R. Taylor
Alaska Attorney General

Kris Mayes
Arizona Attorney General

Tim Griffin
Arkansas Attorney General
Rob Bonta  
California Attorney General

Phil Weiser  
Colorado Attorney General

Kathleen Jennings  
Delaware Attorney General

Brian Schwalb  
District of Columbia Attorney General

Christopher M. Carr  
Georgia Attorney General

Anne E. Lopez  
Hawaii Attorney General

Kwame Raoul  
Illinois Attorney General

Todd Rokita  
Indiana Attorney General

Daniel Cameron  
Kentucky Attorney General

Jeff Landry  
Louisiana Attorney General

Anthony G. Brown  
Maryland Attorney General

Dana Nessel  
Michigan Attorney General
Keith Ellison  
Minnesota Attorney General

Andrew Bailey  
Missouri Attorney General

Aaron D. Ford  
Nevada Attorney General

John M. Formella  
New Hampshire Attorney General

Raúl Torrez  
New Mexico Attorney General

Josh Stein  
North Carolina Attorney General

Gentner Drummond  
Oklahoma Attorney General

Ellen F. Rosenblum  
Oregon Attorney General

Michelle Henry  
Pennsylvania Attorney General

Peter F. Neronha  
Rhode Island Attorney General

Alan Wilson  
South Carolina Attorney General

Marty Jackley  
South Dakota Attorney General
Ken Paxton  
Texas Attorney General

Charity Clark  
Vermont Attorney General

Robert W. Ferguson  
Washington Attorney General

Joshua L. Kaul  
Wisconsin Attorney General

Sean D. Reyes  
Utah Attorney General

Jason S. Miyares  
Virginia Attorney General

Patrick Morrisey  
West Virginia Attorney General